[Tim-3: a novel biomarker and therapeutic target in oncology]. / Tim-3 - Biomarqueur et cible thérapeutique en cancérologie.
Med Sci (Paris)
; 34(3): 231-237, 2018 Mar.
Article
em Fr
| MEDLINE
| ID: mdl-29547109
ABSTRACT
T cells harboring multiple co-inhibitory molecules lose their anti-tumoral functionality. PD-1 is a clinically approved target in cancer therapy, but its expression alone does not mean dysfunctionality. The expression of Tim-3 on numerous cell types (T cell, Treg, dendritic cell, myeloid cells) favors tumor escape to immune cells. Within many tumors, PD-1/Tim-3 coexpressing CD8-T cells lose their ability to secrete cytokines (IFNγ, IL-2, TNFα) and their intratumoral infiltration correlates with a bad prognosis. Tim-3 recently appeared as a potential biomarker of anti-PD-1 resistance. Combined blockade of PD-1 and Tim-3 axis demonstrated potent clinical efficacy in preclinical models and reinforced the rationale of using an anti-Tim-3 to override tumor resistance.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Terapia de Alvo Molecular
/
Receptor Celular 2 do Vírus da Hepatite A
/
Oncologia
Idioma:
Fr
Ano de publicação:
2018
Tipo de documento:
Article